Skip to main content
    T

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.88
    -0.13 (-4.32%)

    Market Cap: $58.49M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tonix Pharmaceuticals Holding Corp (TNXP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Tonix Pharmaceuticals Holding reported revenue of $13.11M for the fiscal year ended Dec 31, 2025, up 29.8% from the year before. That year, net income was -$124.02M with a net margin of -946.2%, operating cash flow was -$99.84M and free cash flow was -$103.21M. The quarter ended Sep 30, 2026 had revenue of $17.23M and net income of -$53.33M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$13.11M+29.8%49.3%-959.1%-946.2%
    Dec 2024$10.09M+29.9%23.1%-1354.3%-1288.3%
    Dec 2023$7.77MN/A39.0%-1523.9%-1501.8%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$13.11M$10.09M$7.77M$0$0$0$0$0$0$0
    Cost of revenue$6.64M$7.76M$4.74M$0$0$0$0$26.32M$0$0
    Gross profit$6.47M$2.33M$3.03M$0$0$0$0-$26.32M$0$0
    Research and development$44.49M$39.97M$86.66M$81.88M$68.84M$36.16M$18.19M$0$13.34M$28.53M
    Operating income-$125.70M-$136.70M-$118.38M-$112.09M-$92.31M-$50.51M-$28.83M-$26.32M-$21.29M-$38.97M
    Net income-$124.02M-$130.04M-$116.66M-$110.22M-$92.29M-$50.46M-$28.62M-$26.09M-$21.12M-$38.84M
    EBITDA-$125.17M-$127.16M-$112.37M-$110.84M-$92.26M-$50.48M-$28.80M$54.00K-$21.22M-$38.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$17.23M$13.54M$6.88M$5.39M$3.29M$2.00M$2.43M$2.58M$2.82M$2.21M$2.48M$3.78M
    Gross profit$15.98M$12.84M$5.30M$4.33M$1.92M-$1.27M$1.49M$1.40M$1.27M-$1.16M$822.00K$1.41M
    Operating income-$55.43M-$42.53M-$41.54M-$48.29M-$33.07M-$28.30M-$16.05M-$22.48M-$15.55M-$77.32M-$21.35M-$27.33M
    Net income-$53.33M-$40.55M-$40.19M-$46.91M-$32.01M-$28.27M-$16.83M-$22.11M-$14.21M-$78.78M-$14.94M-$27.32M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $125.00K by $207.51M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$277.17M$162.89M$154.46M$225.69M$240.90M$98.18M$14.56M$26.32M$26.75M$27.51M
    Current assets$228.88M$119.00M$47.77M$130.78M$189.05M$87.99M$13.95M$26.06M$26.44M$27.14M
    Cash and equivalents$207.64M$98.78M$24.95M$120.23M$178.66M$77.07M$11.25M$25.03M$25.50M$18.94M
    Total liabilities$32.02M$23.33M$48.93M$18.51M$22.18M$10.54M$5.14M$2.65M$2.14M$2.15M
    Short-term debt$125.00K$2.82M$2.35M$0$489.00K$595.00K$352.00KN/AN/AN/A
    Long-term debtN/A$4.67M$6.56M$0N/AN/AN/AN/A$0$0
    Shareholder equity$245.15M$139.56M$105.53M$207.18M$218.72M$87.65M$9.42M$23.66M$24.62M$25.36M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$242.43M$254.09M$257.91M$277.17M$252.44M$187.36M$192.87M$162.89M$94.99M$70.31M$135.34M$154.46M
    Total liabilities$42.94M$31.81M$30.77M$32.02M$21.30M$19.36M$12.47M$23.33M$20.78M$28.20M$27.20M$48.93M
    Cash and equivalents$162.79M$176.23M$185.47M$207.64M$190.06M$125.33M$131.72M$98.78M$28.23M$4.16M$7.05M$24.95M
    Shareholder equity$199.49M$222.28M$227.14M$245.15M$231.14M$168.00M$180.40M$139.56M$74.21M$42.10M$108.14M$105.53M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$99.84M-$60.92M-$102.00M-$98.05M-$75.56M-$48.57M-$26.68M-$23.97M-$19.13M-$37.31M
    Capital expenditures$3.37M$120.00K$7.89M$48.15M$35.31M$8.56M$17.00K$6.00K$5.00K$66.00K
    Free cash flow-$103.21M-$61.05M-$109.90M-$146.20M-$110.86M-$57.13M-$26.70M-$23.98M-$19.13M-$37.38M
    Dividends paid$0$3.00M$0$6.66MN/A$451.00K$2.47M$3.27M$0$0
    Share repurchases$13.76M$0$13.96M$0N/AN/AN/AN/AN/AN/A
    Investing cash flow-$4.53M-$120.00K-$29.07M-$48.15M-$35.31M-$8.56M-$17.00K-$6.00K$7.17M$16.55M
    Financing cash flow$214.53M$134.87M$36.52M$87.84M$212.49M$123.11M$12.92M$23.54M$18.52M$20.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$41.07M-$42.24M-$42.32M-$39.65M-$28.78M-$14.83M-$16.58M-$14.63M-$18.80M-$9.92M-$17.57M-$22.34M
    Capital expenditures$603.00K$587.00K$1.69M$1.87M$962.00K$527.00K$6.00K$3.00K$9.00K$1.76K$108.00K$438.00K
    Free cash flow-$41.68M-$42.83M-$44.01M-$41.52M-$29.74M-$15.36M-$16.59M-$14.63M-$18.81M-$9.92M-$17.68M-$22.78M
    Last 12 quarters

    Frequently Asked Questions About TNXP

    What is Tonix Pharmaceuticals Holding's annual revenue?

    Tonix Pharmaceuticals Holding reported revenue of $13.11M for the fiscal year ended Dec 31, 2025.

    How fast is Tonix Pharmaceuticals Holding's revenue growing?

    Revenue was up 29.8% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Tonix Pharmaceuticals Holding profitable?

    No. Tonix Pharmaceuticals Holding reported net income of -$124.02M for the fiscal year ended Dec 31, 2025, with a net margin of -946.2%.

    How much free cash flow does TNXP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$99.84M minus capital expenditures of $3.37M produced free cash flow of -$103.21M.

    How much debt does Tonix Pharmaceuticals Holding have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $125.00K and cash and equivalents of $207.64M.